A 14-day course of the oral anti-inflammatory drug montelukast didn’t shorten symptom duration in nonhospitalized US adults with mild or moderate COVID-19, finds a randomized controlled clinical trial published today in JAMA Network Open.
This article was originally published on MedicalXpress.com